Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

not_yet_recruiting150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_1

CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

NCT07361029
not_yet_recruitingphase_1

A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07200479

Clinical Trials (2)

Showing 2 of 2 trials
NCT07361029Phase 1

CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

Recruiting
NCT07200479Phase 1

A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
2